Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic tre...
- Autores:
-
Cardona-Mendoza, Andrés Felipe
Ruíz-Patiño, Alejandro
Zatarain Barrón, Zyanya Lucia
Hakim, Fernando
Jiménez, Enrique
Ramón, Juan Fernando
Useche, Nicolás
Bermúdez, Sonia
Pineda, Diego
Cifuentes, Hernando
Rojas Puentes, Leonardo
Ricaurte, Luisa
Pino, Luis Eduardo
Balaña, Carmen
Arrieta, Oscar
Mejía Cordovez, Juan Armando
- Tipo de recurso:
- Fecha de publicación:
- 2018
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/1669
- Acceso en línea:
- http://hdl.handle.net/20.500.12495/1669
https://doi.org/10.1371/journal.pone.0217340
- Palabra clave:
- Neoplasias de tejido nervioso
Compuestos orgánicos
Conformación molecular
- Rights
- License
- Attribution 4.0 International
id |
UNBOSQUE2_f4aa835cc23c14faf1ecdd413b2462f0 |
---|---|
oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/1669 |
network_acronym_str |
UNBOSQUE2 |
network_name_str |
Repositorio U. El Bosque |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib |
title |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib |
spellingShingle |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib Neoplasias de tejido nervioso Compuestos orgánicos Conformación molecular |
title_short |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib |
title_full |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib |
title_fullStr |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib |
title_full_unstemmed |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib |
title_sort |
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib |
dc.creator.fl_str_mv |
Cardona-Mendoza, Andrés Felipe Ruíz-Patiño, Alejandro Zatarain Barrón, Zyanya Lucia Hakim, Fernando Jiménez, Enrique Ramón, Juan Fernando Useche, Nicolás Bermúdez, Sonia Pineda, Diego Cifuentes, Hernando Rojas Puentes, Leonardo Ricaurte, Luisa Pino, Luis Eduardo Balaña, Carmen Arrieta, Oscar Mejía Cordovez, Juan Armando |
dc.contributor.author.none.fl_str_mv |
Cardona-Mendoza, Andrés Felipe Ruíz-Patiño, Alejandro Zatarain Barrón, Zyanya Lucia Hakim, Fernando Jiménez, Enrique Ramón, Juan Fernando Useche, Nicolás Bermúdez, Sonia Pineda, Diego Cifuentes, Hernando Rojas Puentes, Leonardo Ricaurte, Luisa Pino, Luis Eduardo Balaña, Carmen Arrieta, Oscar Mejía Cordovez, Juan Armando |
dc.contributor.orcid.none.fl_str_mv |
Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471] Rojas Puentes, Leonardo [0000-0002-7865-5424] Ruíz-Patiño, Alejandro [0000-0003-1274-9273] |
dc.subject.decs.spa.fl_str_mv |
Neoplasias de tejido nervioso Compuestos orgánicos Conformación molecular |
topic |
Neoplasias de tejido nervioso Compuestos orgánicos Conformación molecular |
description |
Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRβ and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD±15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95%CI 28.5–42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2–21.1) and 9.1 months (95%CI 6.8–16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFRβ and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better outcomes. |
publishDate |
2018 |
dc.date.issued.none.fl_str_mv |
2018 |
dc.date.accessioned.none.fl_str_mv |
2019-09-11T19:59:35Z |
dc.date.available.none.fl_str_mv |
2019-09-11T19:59:35Z |
dc.type.spa.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.local.spa.fl_str_mv |
artículo |
dc.identifier.issn.none.fl_str_mv |
1932-6203 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/1669 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1371/journal.pone.0217340 |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
dc.identifier.repourl.none.fl_str_mv |
repourl:https://repositorio.unbosque.edu.co |
identifier_str_mv |
1932-6203 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co |
url |
http://hdl.handle.net/20.500.12495/1669 https://doi.org/10.1371/journal.pone.0217340 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofseries.spa.fl_str_mv |
Plos ONE, 1932-6203, Vol. 14, Nro. 16, 2018, p. 1-13 |
dc.relation.uri.none.fl_str_mv |
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217340 |
dc.rights.*.fl_str_mv |
Attribution 4.0 International |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
dc.rights.local.spa.fl_str_mv |
Acceso abierto |
dc.rights.accessrights.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf359 |
dc.rights.creativecommons.none.fl_str_mv |
2019 |
rights_invalid_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Acceso abierto http://purl.org/coar/access_right/c_abf359 2019 http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Springer |
dc.publisher.journal.spa.fl_str_mv |
Plos ONE |
institution |
Universidad El Bosque |
bitstream.url.fl_str_mv |
http://18.204.144.38/bitstreams/3907223f-8451-432f-8ac2-40c5c133cf9a/download http://18.204.144.38/bitstreams/3e4880e0-7735-434e-91f4-8302b981716f/download http://18.204.144.38/bitstreams/74c40204-bab4-45f6-9703-d5b751280ed6/download http://18.204.144.38/bitstreams/b9503268-619e-4df4-beff-05b6c25318e3/download http://18.204.144.38/bitstreams/a246d226-5b58-43c2-b7b6-1c13e7952f05/download |
bitstream.checksum.fl_str_mv |
863fb1f110076b266bb6cc4e4194047d 8a4605be74aa9ea9d79846c1fba20a33 0175ea4a2d4caec4bbcc37e300941108 02abee04e740e8ac2d5667e2cc1753ec 5c649a013b2501f01170244736907a39 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
DSpace Pre-instalado Biteca S.A.S |
repository.mail.fl_str_mv |
bibliotecas@biteca.com |
_version_ |
1808397359985459200 |
spelling |
Cardona-Mendoza, Andrés FelipeRuíz-Patiño, AlejandroZatarain Barrón, Zyanya LuciaHakim, FernandoJiménez, EnriqueRamón, Juan FernandoUseche, NicolásBermúdez, SoniaPineda, DiegoCifuentes, HernandoRojas Puentes, LeonardoRicaurte, LuisaPino, Luis EduardoBalaña, CarmenArrieta, OscarMejía Cordovez, Juan ArmandoCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]Rojas Puentes, Leonardo [0000-0002-7865-5424]Ruíz-Patiño, Alejandro [0000-0003-1274-9273]2019-09-11T19:59:35Z2019-09-11T19:59:35Z20181932-6203http://hdl.handle.net/20.500.12495/1669https://doi.org/10.1371/journal.pone.0217340instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengSpringerPlos ONEPlos ONE, 1932-6203, Vol. 14, Nro. 16, 2018, p. 1-13https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217340Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf3592019http://purl.org/coar/access_right/c_abf2Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinibarticleartículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Neoplasias de tejido nerviosoCompuestos orgánicosConformación molecularPurpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRβ and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD±15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95%CI 28.5–42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2–21.1) and 9.1 months (95%CI 6.8–16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFRβ and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better outcomes.ORIGINALCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdfCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdfapplication/pdf1111330http://18.204.144.38/bitstreams/3907223f-8451-432f-8ac2-40c5c133cf9a/download863fb1f110076b266bb6cc4e4194047dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://18.204.144.38/bitstreams/3e4880e0-7735-434e-91f4-8302b981716f/download8a4605be74aa9ea9d79846c1fba20a33MD53CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908http://18.204.144.38/bitstreams/74c40204-bab4-45f6-9703-d5b751280ed6/download0175ea4a2d4caec4bbcc37e300941108MD52THUMBNAILCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.jpgCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.jpgIM Thumbnailimage/jpeg12982http://18.204.144.38/bitstreams/b9503268-619e-4df4-beff-05b6c25318e3/download02abee04e740e8ac2d5667e2cc1753ecMD54TEXTCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.txtCardona A.F., Ruiz-Patiño A., Zatarain-Barrón Z.L..pdf.txtExtracted texttext/plain47528http://18.204.144.38/bitstreams/a246d226-5b58-43c2-b7b6-1c13e7952f05/download5c649a013b2501f01170244736907a39MD5520.500.12495/1669oai:18.204.144.38:20.500.12495/16692024-02-06 22:05:01.833http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttp://18.204.144.38DSpace Pre-instalado Biteca S.A.Sbibliotecas@biteca.comTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo= |